Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg; Samar Issa; Katerina Bakunina; Monique C. Minnema; Tatjana Seute; Marc Durian; Gavin Cull; Harry C. Schouten; Wendy B. C. Stevens; Josee M. Zijlstra; Joke W. Baars; Marcel Nijland; Kylie D. Mason; Aart Beeker; Martini van den Bent; Max Beijert; Michael Gonzales; Daphne de Jong; Jeanette K. Doorduijn

doi:10.1016/S1470-2045(18)30747-2

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg^*, Samar Issa, Katerina Bakunina, Monique C. Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Harry C. Schouten, Wendy B. C. Stevens, Josee M. Zijlstra, Joke W. Baars, Marcel Nijland, Kylie D. Mason, Aart Beeker, Martini van den Bent, Max Beijert, Michael Gonzales, Daphne de Jong, Jeanette K. Doorduijn

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	216-228
Number of pages	13
Journal	Lancet oncology
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/S1470-2045(18)30747-2
Publication status	Published - Feb 2019

Keywords

NERVOUS-SYSTEM LYMPHOMA
WHOLE-BRAIN RADIOTHERAPY
HIGH-DOSE METHOTREXATE
ELDERLY-PATIENTS
IMPROVED SURVIVAL
CHEMOTHERAPY
IMMUNOCHEMOTHERAPY
TEMOZOLOMIDE
PROCARBAZINE
CYTARABINE

Access to Document

10.1016/S1470-2045(18)30747-2

Cite this

Bromberg, J. E. C., Issa, S., Bakunina, K., Minnema, M. C., Seute, T., Durian, M., Cull, G., Schouten, H. C., Stevens, W. B. C., Zijlstra, J. M., Baars, J. W., Nijland, M., Mason, K. D., Beeker, A., van den Bent, M., Beijert, M., Gonzales, M., de Jong, D., & Doorduijn, J. K. (2019). Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet oncology, 20(2), 216-228. https://doi.org/10.1016/S1470-2045(18)30747-2

Bromberg, Jacoline E. C. ; Issa, Samar ; Bakunina, Katerina ; Minnema, Monique C. ; Seute, Tatjana ; Durian, Marc ; Cull, Gavin ; Schouten, Harry C. ; Stevens, Wendy B. C. ; Zijlstra, Josee M. ; Baars, Joke W. ; Nijland, Marcel ; Mason, Kylie D. ; Beeker, Aart ; van den Bent, Martini ; Beijert, Max ; Gonzales, Michael ; de Jong, Daphne ; Doorduijn, Jeanette K. / Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24) : a randomised, open-label, phase 3 intergroup study. In: Lancet oncology. 2019 ; Vol. 20, No. 2. pp. 216-228.

@article{08d693eae52844b1b17930d107e3cc38,

title = "Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study",

keywords = "NERVOUS-SYSTEM LYMPHOMA, WHOLE-BRAIN RADIOTHERAPY, HIGH-DOSE METHOTREXATE, ELDERLY-PATIENTS, IMPROVED SURVIVAL, CHEMOTHERAPY, IMMUNOCHEMOTHERAPY, TEMOZOLOMIDE, PROCARBAZINE, CYTARABINE",

author = "Bromberg, {Jacoline E. C.} and Samar Issa and Katerina Bakunina and Minnema, {Monique C.} and Tatjana Seute and Marc Durian and Gavin Cull and Schouten, {Harry C.} and Stevens, {Wendy B. C.} and Zijlstra, {Josee M.} and Baars, {Joke W.} and Marcel Nijland and Mason, {Kylie D.} and Aart Beeker and {van den Bent}, Martini and Max Beijert and Michael Gonzales and {de Jong}, Daphne and Doorduijn, {Jeanette K.}",

year = "2019",

month = feb,

doi = "10.1016/S1470-2045(18)30747-2",

language = "English",

volume = "20",

pages = "216--228",

journal = "Lancet oncology",

issn = "1470-2045",

publisher = "Elsevier Science",

number = "2",

}

Bromberg, JEC, Issa, S, Bakunina, K, Minnema, MC, Seute, T, Durian, M, Cull, G, Schouten, HC, Stevens, WBC, Zijlstra, JM, Baars, JW, Nijland, M, Mason, KD, Beeker, A, van den Bent, M, Beijert, M, Gonzales, M, de Jong, D & Doorduijn, JK 2019, 'Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study', Lancet oncology, vol. 20, no. 2, pp. 216-228. https://doi.org/10.1016/S1470-2045(18)30747-2

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24) : a randomised, open-label, phase 3 intergroup study. / Bromberg, Jacoline E. C.; Issa, Samar; Bakunina, Katerina; Minnema, Monique C.; Seute, Tatjana; Durian, Marc; Cull, Gavin; Schouten, Harry C.; Stevens, Wendy B. C.; Zijlstra, Josee M.; Baars, Joke W.; Nijland, Marcel; Mason, Kylie D.; Beeker, Aart; van den Bent, Martini; Beijert, Max; Gonzales, Michael; de Jong, Daphne; Doorduijn, Jeanette K.

In: Lancet oncology, Vol. 20, No. 2, 02.2019, p. 216-228.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24)

T2 - a randomised, open-label, phase 3 intergroup study

AU - Bromberg, Jacoline E. C.

AU - Issa, Samar

AU - Bakunina, Katerina

AU - Minnema, Monique C.

AU - Seute, Tatjana

AU - Durian, Marc

AU - Cull, Gavin

AU - Schouten, Harry C.

AU - Stevens, Wendy B. C.

AU - Zijlstra, Josee M.

AU - Baars, Joke W.

AU - Nijland, Marcel

AU - Mason, Kylie D.

AU - Beeker, Aart

AU - van den Bent, Martini

AU - Beijert, Max

AU - Gonzales, Michael

AU - de Jong, Daphne

AU - Doorduijn, Jeanette K.

PY - 2019/2

Y1 - 2019/2

KW - NERVOUS-SYSTEM LYMPHOMA

KW - WHOLE-BRAIN RADIOTHERAPY

KW - HIGH-DOSE METHOTREXATE

KW - ELDERLY-PATIENTS

KW - IMPROVED SURVIVAL

KW - CHEMOTHERAPY

KW - IMMUNOCHEMOTHERAPY

KW - TEMOZOLOMIDE

KW - PROCARBAZINE

KW - CYTARABINE

U2 - 10.1016/S1470-2045(18)30747-2

DO - 10.1016/S1470-2045(18)30747-2

M3 - Article

VL - 20

SP - 216

EP - 228

JO - Lancet oncology

JF - Lancet oncology

SN - 1470-2045

IS - 2

ER -